Different levels of synergistic effects were observed when combining X4-136 with anti-PD-1, anti-PD-L1, or anti-CXCR4, including retardation of tumor growth, decline in regulatory T cells and infiltration of CD8+ cell, implying X4-136 is a pertinent agent to immune checkpoint inhibitors [129]. Here, CD8A is linked to neoplasm.